Evidence map›Paper›PMID 34290523›Full record

ArticleInternational journal of general medicine2021

Prognostic Value and Significant Pathway Exploration Associated with TOP2A Involved in Papillary Thyroid Cancer.

Mou-Chun Gong, Wei-Qing Chen, Zhao-Qing Jin, Jia Lyu, Li-Hao Meng, Hai-Yan Wu, Fei-Hua Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mou-Chun Gong *Department of General Surgery, First People's Hospital of Hangzhou Lin'an District, Hangzhou, Zhejiang, 311300, People's Republic of China.
Wei-Qing Chen *Department of General Surgery, First People's Hospital of Hangzhou Lin'an District, Hangzhou, Zhejiang, 311300, People's Republic of China.
Zhao-Qing JinDepartment of General Surgery, First People's Hospital of Hangzhou Lin'an District, Hangzhou, Zhejiang, 311300, People's Republic of China.
Jia LyuDepartment of General Surgery, First People's Hospital of Hangzhou Lin'an District, Hangzhou, Zhejiang, 311300, People's Republic of China.
Li-Hao MengDepartment of General Surgery, First People's Hospital of Hangzhou Lin'an District, Hangzhou, Zhejiang, 311300, People's Republic of China.
Hai-Yan WuDepartment of General Surgery, First People's Hospital of Hangzhou Lin'an District, Hangzhou, Zhejiang, 311300, People's Republic of China.
Fei-Hua ChenDepartment of General Surgery, First People's Hospital of Hangzhou Lin'an District, Hangzhou, Zhejiang, 311300, People's Republic of China.
Hangzhou First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTopoisomerase 2-alpha (TOP2A) has been identified as a hub gene that played an important role in the initiation and progression of thyroid carcinoma (THCA). However, the exact function of TOP2A in papillary thyroid cancer (PTC) remained elusive. The current study aimed to evaluate the TOP2A expression, prognosis significance and key signaling pathways involved in PTC.

methodsWe firstly evaluated the expression of TOP2A in PTC via UALCAN, cBioportal, HPA and LinkdedOmics databases. Genetic alteration of TOP2A in PTC was then explored in cBioportal. Prognostic impacts of TOP2A expression on disease-free survival (DFS) of PTC patients were subsequently evaluated using Kaplan-Meier plotter and Gepia databases. Taking gender, age, cancer stage, T, N and M stages into consideration, we compared survival difference between TOP2A high and low expression groups. KEGG pathway analysis in WebGestalt and GSEA analysis were further performed to reveal the potential TOP2A-associated signaling pathways involved in PTC. Finally, the upstream microRNAs of TOP2A were assessed using DIANA, TargetScan, miRDB and miRWALK database, followed by mechanism exploration of upstream microRNAs.

results1) The mRNA and protein of TOP2A were highly expressed in PTC tissue compared with normal thyroid tissue. TOP2A expression was associated with patient's age, N stage and cancer stage (all

conclusionThe expression of TOP2A was higher in PTC tissue, which resulted in a worse DFS of patients with PTC. TOP2A might act as an effective therapeutic target for PTC treatment.

Indexed as

high expressionpathwaypoor prognosisTOP2A

Identifiers

PMID34290523
PMCPMC8289466
OpenAlexW3181134488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.